{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Sage Therapeutics Announces R&amp;D Leadership Transition - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"GEOTYoLLcy\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-announces-rd-leadership-transition\/\">Sage Therapeutics Announces R&amp;D Leadership Transition<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/sage-therapeutics-announces-rd-leadership-transition\/embed\/#?secret=GEOTYoLLcy\" width=\"600\" height=\"338\" title=\"&#8220;Sage Therapeutics Announces R&amp;D Leadership Transition&#8221; &#8212; Market Newsdesk\" data-secret=\"GEOTYoLLcy\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Sage Therapeutics Announces R&amp;D Leadership Transition CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company\u2019s product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. \u201cI would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions,\u201d said Barry Greene, Chief Executive Officer of Sage Therapeutics. \u201cLaura has been a relentless advocate for &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250304999395r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"}